CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect - PubMed
6 hours ago
- #AML
- #CLL-1
- #CAR T cells
- CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody (mAb 2-23) show significant anti-AML effects.
- mAb 2-23 exhibits greater affinity for CLL-1 compared to previous antibodies, enhancing cytokine production and cytotoxicity against AML cells.
- Treatment with 2-23 CAR T cells eradicated AML cells and prolonged survival in AML xenograft models.
- Revumenib, a menin inhibitor, increased CLL-1 expression in AML cells with MLL fusion genes or NPM1 mutation, enhancing susceptibility to 2-23 CAR T cells.
- Combination therapy of 2-23 CAR T cells and revumenib may benefit patients with CLL-1low/- AML.
- The study suggests clinical testing of 2-23 CAR T cells for CLL-1-positive AML patients.